Key Highlights
- Kestra secures $196 million funding round
- Funding supports expansion and commercialization of WCD
- Co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds
- ASSURE system prescribed to over 10,000 patients
- Includes support from Bain Capital and Endeavour Vision
Source: Business Wire
Notable Quotes
- “This oversubscribed financing is validation of the excitement and confidence that new and existing investors have for Kestra and our ASSURE cardiac recovery system.” — Brian Webster, President & CEO at Kestra Medical Technologies
- “We are impressed with the clinical performance of the Kestra technology, their patient-focused approach and moreover, the exciting opportunity to penetrate this large and growing patient population.” — Aneta Sottil, Partner at Andera Partners
- “We are proud to continue our long-time support of Kestra and its people-driven mission to protect patients with technologies that are intuitive, intelligent, and mobile.” — Chris Gordon, Partner at Bain Capital
SoHC's Take
Kestra Medical Technologies’ recent $196 million funding round marks a significant milestone in advancing the Wearable Cardioverter Defibrillator (WCD) market. The participation of major investors underscores the confidence in Kestra’s innovative ASSURE system, which has already benefitted over 10,000 patients. This funding will enable Kestra to expand its commercial organization and further penetrate the $1 billion WCD market, potentially transforming cardiac care with its cutting-edge technology and patient-focused solutions.
